Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
GlobeNewswire
· Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure..